Cardiac Risk Management with Hydroxychloroquine Treatment
Patient Risk Factors and Medication Interactions
- The American Society of Clinical Oncology recommends particular caution when using hydroxychloroquine with other QT-prolonging medications, such as other macrolides, quinolones, tyrosine kinase inhibitors, doxorubicin, ondansetron, and serotonin reuptake inhibitors 1
- Concomitant use of other QT-prolonging medications, particularly macrolides and quinolones, can increase the risk of QT prolongation and subsequent arrhythmias 2, 3
- Patients with a history of heart disease, pre-existing bradycardia, or prolonged QT interval before therapy are at increased risk of cardiac events, according to the British Thoracic Society 4
- Advanced age (>80 years) and female sex are demographic factors that contribute to the risk of cardiac events 4, 2
- Baseline QTc prolongation (≥500 ms) and congenital long QT syndrome are patient-specific factors that increase the risk of azithromycin-induced QT prolongation 2
- Hypokalemia and hypomagnesemia are electrolyte abnormalities that can increase the risk of cardiac events 4, 2
- Fever and inflammatory states are concurrent conditions that increase the risk of azithromycin-induced QT prolongation 2
Screening and Monitoring
- The British Thoracic Society recommends screening for history of heart disease, previous low serum potassium, slow pulse rate, family history of sudden death, or known prolonged QT interval before initiating therapy 4
- The American College of Cardiology recommends obtaining a baseline ECG prior to azithromycin administration, especially in high-risk patients, to assess baseline risk 2
- The American College of Cardiology recommends reviewing the patient's medication list for other QT-prolonging drugs and checking electrolyte levels, particularly potassium and magnesium, to assess baseline risk 2
- Perform follow-up ECG one month after initiating therapy to monitor for cardiac events 4
- The American College of Cardiology recommends monitoring ECG during therapy in high-risk patients and maintaining normal electrolyte levels to minimize arrhythmia risk 2
- The Military Medical Research recommends considering ECG monitoring at 5 and 10 days after starting hydroxychloroquine treatment, especially in high-risk patients 3
Treatment Regimens and Cardiac Events
- Higher risk of cardiac events was observed in COVID-19 patients treated with high-dose hydroxychloroquine, according to the Military Medical Research 3
- In a randomized, double-blinded trial, high-dose chloroquine (600 mg twice daily) showed increased QTc prolongation and mortality compared to lower doses, as reported by the Military Medical Research 3
- Fatal cardiac events occur in approximately 85 deaths per 1 million courses prescribed in high-risk groups, according to the British Thoracic Society 4
- The risk of fatal ventricular arrhythmia with macrolides compared to amoxicillin is estimated at 1:4100 among high cardiovascular risk patients and <1:100,000 among low cardiovascular risk patients, according to the European Respiratory Journal guidelines 5
- Azithromycin can prolong the QT interval, potentially leading to serious cardiac arrhythmias, including torsades de pointes, although this is a rare adverse effect, and the risk appears higher with intravenous administration compared to oral administration, as noted by the American College of Cardiology 2